

**OPVEE**
(nalmeferene) NASAL SPRAY 2.7mg



DURING AN OPIOID OVERDOSE,
**EVERY SECOND
MATTERS**^{1,2}

OPVEE® is for emergency treatment of known or suspected overdose induced by natural or synthetic opioids in patients 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE® is for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.³

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: Do not use in patients who are allergic to nalmeferene or any of the other ingredients.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression: While the duration of action of nalmeferene is as long as most opioids, a recurrence of slowed breathing (respiratory depression) is possible after treatment with OPVEE®. Watch patients and give repeat doses of OPVEE® using a new device, as necessary, while awaiting emergency medical assistance.

**Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.**

As the opioid epidemic evolves, so must we

1971

NALOXONE (IV/IM) IS APPROVED⁵

The US Food and Drug Administration (FDA) approves naloxone hydrochloride for intravenous (IV) and intramuscular (IM) administrations to treat opioid overdose.

1970

OVERDOSE DEATHS RISE⁴



About 7100 drug overdose deaths are reported in the US.



1999

WAVE 1 BEGINS⁶⁻⁹

The opioid epidemic began in 1999 with increased prescribing of opioids. Between 1999 and 2010, rates of prescriptions and overdose deaths tripled.

Leading the wave was OxyContin®, marketed as "less addictive" than some of its predecessors when it hit the market in 1995.

⚠️ 8050 deaths are attributed to opioid overdose this year.

2001

THE FDA FOCUSES ON REDUCING OPIOID PRESCRIPTION ABUSE¹⁰

The FDA begins its educational and legal effort to curtail prescription opioid abuse.

2009

DEATHS CONTINUE TO RISE⁹

⚠️ 20,422 opioid overdose deaths this year:

48%

Natural and semisynthetic opioids, including some prescription opioids like OxyContin®

23%

Methadone

16%

Heroin

14%

Synthetic opioids other than methadone



IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists: Improvement in respiratory depression caused by medicines such as buprenorphine and pentazocine may not be complete. Repeat doses of OPVEE® may be required.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

2010

WAVE 2 BEGINS^{6,7,11}

The second wave of the opioid epidemic begins with an increase in heroin-related overdoses.

More than **80%** of heroin users report misusing prescription opioids before using heroin.



2013

WAVE 3 BEGINS^{7,12-14}

An increase in deaths related to synthetic opioids, like fentanyl, marks a new period in the opioid epidemic.

Synthetic opioids are detected circulating in the heroin drug supply. They are cost-effective for drug traffickers because they can be produced in illegal labs and made to look like a variety of medications and other drugs.

2014

THE DEA SEES AN INCREASE IN FENTANYL SEIZURES¹⁵

The US Drug Enforcement Administration (DEA) sees more than 4500 illicit fentanyl seizures—a drastic increase from 618 seizures in 2012.



Even a very small dose —2 mg— can result in a life-threatening overdose.¹⁴

Image: NH State Police Forensics Laboratory.¹⁶

2015

DEATHS CONTINUE TO RISE^{9,12}

Overdose deaths from opioids reach over 30,000—more than quadruple the rate from 1999.

Of these,

⚠ 9580

deaths were caused by synthetic opioids, representing almost 35% of all opioid overdose deaths.

According to drug seizure data from the DEA National Forensics Laboratory Information Service, fentanyl reports increased

↑ 1400%

between 2013 and 2015.

2015

NARCAN® (naloxone HCl) NASAL SPRAY IS APPROVED^{17,18}

The FDA approves NARCAN® to treat opioid overdose.

2017

THE NIH CALLS FOR BETTER¹⁹

The National Institutes of Health (NIH) resolves to work with private partners to develop stronger, longer-acting formulations of antagonists, including naloxone, to counteract the very high-potency synthetic opioids that are now claiming thousands of lives each year.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may cause symptoms of opioid withdrawal like body aches, fever, sweating, runny nose, sneezing, goose bumps, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and rapid heart rate. Some patients may become aggressive when an opioid overdose is treated.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

2023

2022

PROVISIONAL DATA FROM 2022 ESTIMATES THAT SYNTHETIC OPIOIDS, LIKE FENTANYL, CAUSE ABOUT 90% OF ALL OPIOID OVERDOSE DEATHS^{14,23,32,*}

Illicit fentanyl is primarily manufactured in illegal foreign labs and smuggled into the US, where it spreads through the illicit drug supply.



6 out of 10 pills seized by the DEA contain a potentially deadly amount of fentanyl.

*2022 data based on predicted provisional drug overdose death counts from the Centers for Disease Control and Prevention (CDC), last updated May 7, 2023.

2021

OVER 106,000 PEOPLE DIE FROM A DRUG OVERDOSE^{26,29-31}

More than 80,400, or 75%, of overall deaths are caused by opioids. Of the opioid overdose deaths, 88% involved synthetic opioids.

Synthetic opioids are a leading cause of death in people aged **18 to 45**.

Overdose deaths involving synthetic opioids increased by nearly **637%** in 6 years, 2015-2021.

2020

THE COVID-19 PANDEMIC EXACERBATES THE SYNTHETIC OPIOID CRISIS²³⁻²⁸

When the nation entered lockdown in early 2020 for COVID-19, resources were diverted, many people could not reach treatment centers, access to medications for opioid use disorder disappeared, and access to illicit drugs increased over social media.

71% of adolescent overdose deaths involved illicit fentanyl and other synthetics.

2017

A PUBLIC HEALTH EMERGENCY IS DECLARED²⁰⁻²²

The US government declares the opioid epidemic a public health emergency.



OPVEE[®] (nalmefene) NASAL SPRAY IS APPROVED³

OPVEE[®] is the first and only nasal opioid overdose rescue medicine specifically indicated for synthetic opioids, like fentanyl, as well as nonsynthetic opioids.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients with preexisting CV disorders or who received other drugs with similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting.

In newborns, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for symptoms of opioid withdrawal.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.



The opioid epidemic has changed... and continues to evolve

Recent rises in overdose deaths have been fueled by fentanyl and other synthetic opioids^{9,23}

BY 2015:

Nearly 30%

of all opioid overdose deaths were caused by synthetic opioids like fentanyl⁹

IN 2022:

About 90%

of all opioid overdose deaths are caused by synthetic opioids like fentanyl^{23,*}

*Data based on 2022 predicted provisional drug overdose death counts from the CDC, last updated May 7, 2023.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Opioid Overdose from Attempts to Overcome the Blockade: Taking large or repeated doses of opioids, such as heroin or prescription pain pills to overcome blockade, may lead to opioid intoxication and death.

**Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.**



Synthetic opioids pose a triple threat

They're fast³³

They're long-lasting^{2,34}

They're strong²⁶

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS: Most common adverse reactions (incidence at least 2%) are nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion, throat irritation, pain in the nose, decreased appetite, changes in sense of taste, skin redness, and increased sweating.

To report a pregnancy or side effects associated with taking OPVEE® or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



Synthetic opioids can
**INDUCE OVERDOSE
IN MINUTES**³³

Synthetic opioids pose a triple threat

They're fast³³

They're long-lasting^{2,34}

They're strong²⁶

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: Do not use in patients who are allergic to nalmefene or any of the other ingredients.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression: While the duration of action of nalmefene is as long as most opioids, a recurrence of slowed breathing (respiratory depression) is possible after treatment with OPVEE®. Watch patients and give repeat doses of OPVEE® using a new device, as necessary, while awaiting emergency medical assistance.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



Fentanyl has a quick effect but
**STAYS IN THE BODY
A LONG TIME**^{2,34}

Reoverdose can occur when the rescue medicine loses effect while opioids are still in the system, requiring additional doses of rescue medicine.³⁴

Synthetic opioids pose a triple threat

They're fast³³

They're long-lasting^{2,34}

They're strong²⁶



Fentanyl is up to
**50x STRONGER
THAN HEROIN AND
100x STRONGER
THAN MORPHINE**²⁶

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists: Improvement in respiratory depression caused by medicines such as buprenorphine and pentazocine may not be complete. Repeat doses of OPVEE® may be required.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

Opioid relative strength compared with morphine

ILLUSTRATIVE

Morphine milligram equivalents^{26,34-36}



*Relative strength reflects 1 mg to 20 mg of methadone per day; note that relative strength is increased at higher doses.³⁶

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may cause symptoms of opioid withdrawal like body aches, fever, sweating, runny nose, sneezing, goose bumps, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and rapid heart rate. Some patients may become aggressive when an opioid overdose is treated.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

Overdose reversal is a race against time

Time is critical when reversing an opioid overdose. Rapid restoration of normal breathing may help minimize long-term damage or death.^{34,37,38}

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients with preexisting CV disorders or who received other drugs with similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting.

In newborns, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for symptoms of opioid withdrawal.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

Overdoses have an even broader impact when we look beyond overdose deaths

For each opioid-induced fatality, it was estimated that there are between

6.4 and **8.4**

nonfatal overdoses, which takes a toll on overdose victims and society²

Synthetic opioids pose a more dangerous challenge²³

We could benefit from additional overdose rescue medicine options³⁹⁻⁴²

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Opioid Overdose from Attempts to Overcome the Blockade: Taking large or repeated doses of opioids, such as heroin or prescription pain pills to overcome blockade, may lead to opioid intoxication and death.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



OPVEE[®] (nalmefene) Nasal Spray pharmacodynamic* and pharmacokinetic[†] studies³

*Pharmacodynamic studies evaluate what actions a drug might have on the body.⁴³

[†]Pharmacokinetic studies assess how the body interacts with a drug from its administration to the time it is excreted from the body.
This includes absorption, distribution, metabolism, and excretion.⁴⁴

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS: Most common adverse reactions (incidence at least 2%) are nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion, throat irritation, pain in the nose, decreased appetite, changes in sense of taste, skin redness, and increased sweating.

To report a pregnancy or side effects associated with taking OPVEE[®] or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

**Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.**



Pharmacodynamic study trial design overview

A 2-part, open-label, experimental model evaluating pharmacodynamic effects of OPVEE® (nalmefene) Nasal Spray compared with intranasal (IN) naloxone to reverse remifentanil-induced suppression of carbon dioxide (CO₂)-induced increases in minute ventilation (MV)^{3,45,46}

Part 1⁴⁶

Healthy volunteers (n=15)

Primary Objective:
To determine the relationship between remifentanil dose and suppression of CO₂-induced increases in MV

Part 2^{45,46}



*Hypercapnic gas mixture was given to elevate MV and was continued for the duration of the study, excluding mask holidays.⁴⁵

†Following 10 minutes of hypercapnic gas mixture, remifentanil (IV bolus [0.5 µg/kg] + infusion [0.175 µg/kg/min]) was administered for 15 minutes prior to test agents and continued for the duration of the study.^{3,45}

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: Do not use in patients who are allergic to nalmefene or any of the other ingredients.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression: While the duration of action of nalmefene is as long as most opioids, a recurrence of slowed breathing (respiratory depression) is possible after treatment with OPVEE®. Watch patients and give repeat doses of OPVEE® using a new device, as necessary, while awaiting emergency medical assistance.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



OPVEE® (nalmefene) Nasal Spray reversed remifentanil-induced respiratory depression by an average of 98.9% at 5 minutes^{3,45}


The clinical relevance of these findings to a real-world overdose is unknown.

At 5 minutes, the mean increase in MV was 5.745 L/min (98.9% of pre-remifentanil levels).^{3,45}

Full recovery of respiratory drive was noted as early as 5 minutes (between 5 and 15 minutes) after OPVEE® administration.³



PERCENTAGE RECOVERY OF RESPIRATORY DRIVE IN HEALTHY ADULT VOLUNTEERS TREATED WITH OPVEE®^{3,45,46}



Values are represented as mean +/- standard deviation. The dashed line represents the baseline MV, artificially increased due to CO₂ administration, prior to remifentanil administration.³

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists: Improvement in respiratory depression caused by medicines such as buprenorphine and pentazocine may not be complete. Repeat doses of OPVEE® may be required.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



Two PK studies were conducted to assess OPVEE[®] (nalmefene) Nasal Spray³

PK-001

In 68 healthy adult subjects, the relative bioavailability and other pharmacokinetic parameters of one 2.7-mg spray of OPVEE[®] in one nostril was compared with a single dose of nalmefene 1.0 mg administered as an intramuscular injection.

PK-002

In 24 healthy adult subjects, one 2.7-mg spray of OPVEE[®] in one nostril was compared with two 2.7-mg sprays of OPVEE[®] in one nostril and one 2.7-mg spray of OPVEE[®] in each nostril to compare the pharmacokinetics following 3 different dosing regimens.

The mean half-life* of OPVEE[®] in both studies was 11.4 hours.³

*The length of time needed for the concentration of a drug to decrease to half of its starting concentration in the body.⁴⁷

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may cause symptoms of opioid withdrawal like body aches, fever, sweating, runny nose, sneezing, goose bumps, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and rapid heart rate. Some patients may become aggressive when an opioid overdose is treated.

**Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.**

Two PK studies were conducted to assess OPVEE[®] (nalmeфene) Nasal Spray³

	C_{max}^*	T_{max}^{\S}	Half-life	Number of subjects
Data from study PK-001				
OPVEE [®] (intranasal)	10.4 ng/mL (62.6) [†]	15 mins (0.0833-2.0 hrs)	11.4 hours (20.8)	68
Nalmeфene (1 mg intramuscular)	1.5 ng/mL (59.4) [†]	19.8 mins (0.117-18.0 hrs)	10.6 hours (18.5)	68
Data from study PK-002				
Single dose (2.7 mg)	9.75 ng/mL (49.4) [‡]	16 mins (0.167-2.03 hrs)	11.4 hours (22.0)	24
One dose in each nostril (5.4 mg)	18.9 ng/mL (88.0) [‡]	15 mins (0.117-3.0 hrs)	11.3 hours (16.6)	24
Two doses in same nostril (5.4 mg)	16.1 ng/mL (62.9) [‡]	15 mins (0.117-2.03 hrs)	11.3 hours (16.5)	24

* C_{max} is the highest concentration of the drug in the blood.⁴⁸

[†] C_{max} presented as arithmetic mean (coefficient of variation percentage).

[‡] C_{max} presented as geometric mean (coefficient of variation percentage).

[§] T_{max} presented as median (range). T_{max} is the time to peak drug concentration (C_{max}).⁴⁹

^{||}Half-life ($t_{1/2}$) presented as arithmetic mean (coefficient of variation percentage).

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients with preexisting CV disorders or who received other drugs with similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting.

In newborns, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for symptoms of opioid withdrawal.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.

Most common adverse reactions in 3 separate studies in healthy adult volunteers³

Study type	Participants	Most common adverse reactions
Pharmacokinetic (PK-001)	66 healthy adult volunteers	Nasal discomfort and dizziness
Pharmacokinetic (PK-002)	24 healthy adult volunteers	Rhinalgia, nasal congestion, nasal discomfort, and nausea
Pharmacodynamic (OOD-001)	61 healthy adult volunteers	Headache, nausea, hot flush, and dizziness

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Opioid Overdose from Attempts to Overcome the Blockade: Taking large or repeated doses of opioids, such as heroin or prescription pain pills to overcome blockade, may lead to opioid intoxication and death.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

Relative Frequencies of Treatment-Related Common Adverse Events That Occurred in Greater Than 2% of Healthy Adult Volunteers³

OPVEE® 2.7 mg

System Organ Class Preferred Term	PD Study, n (%) N=61	PK Studies, n (%) N=89
Respiratory, thoracic, and mediastinal disorders		
Nasal discomfort	5 (8.2%)	38 (42.7%)
Nasal congestion	2 (3.3%)	4 (4.5%)
Throat irritation	3 (4.9%)	3 (3.4%)
Rhinalgia	1 (1.6%)	3 (3.4%)
Dyspnea	2 (3.3%)	0
Oropharyngeal pain	2 (3.3%)	0
Nervous system disorders		
Headache	34 (55.7%)	6 (6.7%)
Dizziness	9 (14.8%)	5 (5.6%)
Dysgeusia	2 (3.3%)	1 (1.1%)
Paresthesia	2 (3.3%)	0
Gastrointestinal disorders		
Nausea	22 (36.1%)	3 (3.4%)
Vomiting	7 (11.5%)	2 (2.2%)

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS: Most common adverse reactions (incidence at least 2%) are nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion, throat irritation, pain in the nose, decreased appetite, changes in sense of taste, skin redness, and increased sweating.

To report a pregnancy or side effects associated with taking OPVEE® or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



Relative Frequencies of Treatment-Related Common Adverse Events That Occurred in Greater Than 2% of Healthy Adult Volunteers³

OPVEE® 2.7 mg

System Organ Class Preferred Term	PD Study, n (%) N=61	PK Studies, n (%) N=89
Vascular disorders		
Hot flush	12 (19.7%)	0
Psychiatric disorders		
Anxiety	7 (11.5%)	0
Agitation	2 (3.3%)	0
Claustrophobia	2 (3.3%)	0
General disorders and administration site conditions		
Fatigue	3 (4.9%)	3 (3.4%)
Chills	2 (3.3%)	0
Skin and subcutaneous tissue disorders		
Erythema	0	3 (3.4%)
Hyperhidrosis	3 (6.6%)	0
Metabolism and nutrition disorders		
Decreased appetite	2 (3.3%)	1 (1.1%)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: Do not use in patients who are allergic to nalmefene or any of the other ingredients.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression: While the duration of action of nalmefene is as long as most opioids, a recurrence of slowed breathing (respiratory depression) is possible after treatment with OPVEE®. Watch patients and give repeat doses of OPVEE® using a new device, as necessary, while awaiting emergency medical assistance.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

OPVEE[®] (nalmefene) Nasal Spray is the first and only nasal opioid rescue medicine specifically indicated for synthetic opioids, like fentanyl³



OPVEE[®] is...

FAST³

LONG-LASTING³

In an experimental model in healthy adult subjects, OPVEE[®] reversed remifentanyl-induced respiratory depression by an average of

98.9% at 5 minutes.³

Full recovery of respiratory drive was noted as early as 5 minutes (between 5 and 15 minutes).³

The clinical relevance of these findings to a real-world overdose is unknown.

If the patient does not respond or responds and then relapses into respiratory depression, readminister OPVEE[®] using a new nasal spray, in the nose, every 2 to 5 minutes.³

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists: Improvement in respiratory depression caused by medicines such as buprenorphine and pentazocine may not be complete. Repeat doses of OPVEE[®] may be required.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.



OPVEE[®] (nalmefene) Nasal Spray is the first and only nasal opioid rescue medicine specifically indicated for synthetic opioids, like fentanyl³



OPVEE[®] is...

FAST³

LONG-LASTING³

In the pharmacokinetic studies, the mean half-life of OPVEE[®] was **11.4 hours**.³

The half-life of fentanyl varies greatly due to many factors, including the route of administration, dose, and formulation. The half-life of illicit fentanyl has not been studied; however, the half-life of fentanyl (when used as anesthesia) has been shown to be about 7.5 hours.^{2,50,51}

The clinical relevance of these findings to a real-world overdose is unknown.

IMPORTANT SAFETY INFORMATION (cont'd)


WARNINGS AND PRECAUTIONS (cont'd)

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may cause symptoms of opioid withdrawal like body aches, fever, sweating, runny nose, sneezing, goose bumps, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and rapid heart rate. Some patients may become aggressive when an opioid overdose is treated.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.



The mean half-life of OPVEE® (nalmefene) Nasal Spray in healthy adult subjects was 11.4 hours³



*Lower range is shown for heroin (0.1-.025) and morphine (1.3-6.7).⁵²

[†]The half-life of fentanyl varies greatly due to many factors, including the route of administration, dose, and formulation. The half-life of illicit fentanyl has not been studied; however, the half-life of fentanyl when used as anesthesia has been shown to be about 7.5 hours.^{2,50,51}

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients with preexisting CV disorders or who received other drugs with similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting.

In newborns, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for symptoms of opioid withdrawal.

**Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.**

With the cause of an opioid overdose often unknown, it's important to be prepared^{2,34,37}

OPVEE® (nalmeфene) Nasal Spray is fast³

OPVEE® is long-lasting³



Not actual size.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Opioid Overdose from Attempts to Overcome the Blockade: Taking large or repeated doses of opioids, such as heroin or prescription pain pills to overcome blockade, may lead to opioid intoxication and death.

Please see additional Important Safety Information throughout. See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.

OPVEE® (nalmefene) Nasal Spray has a 28-month shelf life^{53,*}

STORE OPVEE®

BETWEEN

 **59 °F** and **77 °F**³

(15 °C and 25 °C)

SHORT-TERM EXCURSIONS
PERMITTED

BETWEEN

 **39 °F** and **104 °F**³

(4 °C and 40 °C)

 **Do not freeze. Protect from light.**³

Store OPVEE® in the blister and cartons provided.

Do not open individual blister packs or test nasal spray devices before use.

Each unit-dose nasal spray device sprays one (1) time and cannot be re-used.

*From date of manufacture.

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS: Most common adverse reactions (incidence at least 2%) are nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion, throat irritation, pain in the nose, decreased appetite, changes in sense of taste, skin redness, and increased sweating.

To report a pregnancy or side effects associated with taking OPVEE® or any safety related information, product complaint, request for medical information, or product query, please contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE® at www.OPVEE.com.



Not actual size.

2 devices per box³

 **OPVEE**
(nalmefene) NASAL SPRAY 2.7mg

Choose OPVEE[®] (nalmefene) Nasal Spray today

Take action now—OPVEE[®] is available to order.
Visit [OPVEEdirect.com](https://www.OPVEEdirect.com).

Qualifying direct purchasers, such as departments of health, emergency medical services, law enforcement, schools/universities, and community organizations, may be eligible to purchase OPVEE[®] at the public interest price, which is \$37.50/dose or \$75/2-pack.*

For other orders, the Wholesale Acquisition Cost (WAC)[†] of OPVEE[®] is \$49/dose or \$98/2-pack.*

*As of October 2, 2023.

[†]The WAC price represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party drug price publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reductions in price. Pricing information listed above does not imply safety or efficacy of the product, and no comparisons should be made.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: Do not use in patients who are allergic to nalmefene or any of the other ingredients.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression: While the duration of action of nalmefene is as long as most opioids, a recurrence of slowed breathing (respiratory depression) is possible after treatment with OPVEE[®]. Watch patients and give repeat doses of OPVEE[®] using a new device, as necessary, while awaiting emergency medical assistance.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.



Not actual size.



[OPVEEdirect.com](https://www.OPVEEdirect.com)



OPVEE[®] (nalmefene) Nasal Spray—a rescue medicine option for today's opioid epidemic

OPVEE[®] is FDA approved³

OPVEE[®] is the first and only nasal opioid overdose rescue medicine specifically indicated for synthetic opioids, like fentanyl, as well as nonsynthetic opioids.

OPVEE[®] is **fast*** and has a **long half-life**.

*In an experimental model of remifentanil-induced respiratory depression in healthy adult subjects.

The safety of OPVEE[®] is supported by safety and pharmacokinetic studies in healthy adult subjects³



OPVEE.com

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists: Improvement in respiratory depression caused by medicines such as buprenorphine and pentazocine may not be complete. Repeat doses of OPVEE[®] may be required.

Please see additional Important Safety Information throughout.
See full Prescribing Information and more information about OPVEE[®] at www.OPVEE.com.



References

1. Somerville NJ, O'Donnell J, Gladden RM, et al. Characteristics of fentanyl overdose – Massachusetts, 2014–2016. *MMWR Morb Mortal Wkly Rep.* 2017;66(14):382-386.
2. Skolnick P. Treatment of overdose in the synthetic opioid era. *Pharmacol Ther.* 2022;233:108019.
3. Prescribing Information for OPVEE®.
4. CDC WONDER Online Database. Compressed mortality file 1968-1978: drug overdose deaths by year 1968-1978. Centers for Disease Control and Prevention. Updated December 16, 2019. Accessed May 12, 2023. <http://wonder.cdc.gov/cmfi-cd8.html>
5. Food and Drug Administration, HHS. Safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use; request for comments. *Fed Regist.* 2022;87(220):68702-68713.
6. Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. *Lancet.* 2022;399(10324):555-604.
7. Understanding the opioid overdose epidemic. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Updated June 1, 2022. Accessed March 7, 2023. <https://www.cdc.gov/opioids/basics/epidemic.html>
8. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. *Annu Rev Public Health.* 2015;36:559-574.
9. Hedegaard H, Miniño AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999-2020. Data table for Figure 4. Age-adjusted rates of drug overdose deaths involving opioids, by type of opioid: United States, 1999-2020. *NCHS Data Brief.* 2021;(428):1-8. Accessed March 8, 2023. <https://www.cdc.gov/nchs/data/databriefs/db428-tables.pdf#5>
10. Timeline of selected FDA activities and significant events addressing substance use and overdose prevention. US Food and Drug Administration. Updated January 31, 2023. Accessed March 7, 2023. <https://www.fda.gov/media/126835/download>
11. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002–2004 and 2008–2010. *Drug Alcohol Depend.* 2013;132(1-2):95-100.
12. Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. *Int J Drug Policy.* 2017;46:107-111.
13. 2020 National Drug Threat Assessment (NDTA). US Drug Enforcement Administration; March 2021. Accessed March 8, 2023. https://www.dea.gov/sites/default/files/2021-02/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf
14. Facts about fentanyl. US Drug Enforcement Administration. Published April 29, 2021. Accessed March 8, 2023. <https://www.dea.gov/resources/facts-about-fentanyl>
15. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities. CDC Health Alert Network Health Advisory No. 384. Centers for Disease Control and Prevention; October 26, 2015. Accessed March 7, 2023. <https://stacks.cdc.gov/view/cdc/35133>
16. Taylor BA; NH State Police Forensic Lab. Heroin v. fentanyl [image]. National Institute of Standards and Technology. Updated July 31, 2019. Accessed March 8, 2023. <https://www.nist.gov/image/17mml015heroinfentanyldemonstrativebat5667jpg>
17. Narcan FDA approval history. Drugs.com. Accessed March 7, 2023. <https://www.drugs.com/history/narcan.html>
18. Prescribing Information for NARCAN®.
19. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. *N Engl J Med.* 2017;377(4):391-394.
20. US Centers for Medicare & Medicaid Services. Ongoing emergencies & disasters. CMS.gov. Updated December 5, 2022. Accessed March 14, 2023. <https://www.cms.gov/about-cms/agency-information/emergency/epr/current-emergencies/ongoing-emergencies>
21. Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. *Pain Ther.* 2018;7(1):13-21.
22. Determination that a public health emergency exists. US Department of Health and Human Services. October 26, 2017. Accessed March 7, 2023. https://www.cms.gov/About-CMS/Agency-Information/Emergency/Downloads/October_26_2017_Public_Health_Declaration_for_Opioids_Crisis.pdf
23. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. National Vital Statistics System. Provisional drug overdose death counts: 12 month-ending provisional number of drug overdose deaths by drug or drug class. National Center for Health Statistics. Updated May 7, 2023. Accessed June 12, 2023. <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
24. CDC Museum COVID-19 timeline. Centers for Disease Control and Prevention. Updated March 15, 2023. Accessed April 28, 2023. <https://www.cdc.gov/museum/timeline/covid19.html>
25. Sarker A, Nataraj N, Siu W, Li S, Jones CM, Sumner SA. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts. *Subst Abuse Treat Prev Policy.* 2022;17(1):16.
26. Cotton T, Trone DJ, Markey E, et al. *Commission on Combating Synthetic Opioid Trafficking: Final Report.* RAND Corporation; February 8, 2022. Accessed March 8, 2023. https://www.rand.org/pubs/external_publications/EP68838.html

References

27. Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. *Addict Sci Clin Pract.* 2021;16(1):68.
28. Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. *JAMA.* 2022;327(14):1398-1400.
29. Spencer MR, Miniño AM, Warner M. Drug overdose deaths in the United States, 2001-2021. *NCHS Data Brief.* 2022;(457):1-8. Accessed March 10, 2023. <https://www.cdc.gov/nchs/data/databriefs/db457-tables.pdf>
30. WISQARS Injury Database. 20 leading causes of death, United States: 2020, all races, both sexes, ages: 18-45. Centers for Disease Control and Prevention. Updated February 20, 2020. Accessed March 8, 2023. <https://wisqars.cdc.gov/fatal-leading>
31. CDC WONDER Online Database. Multiple cause of death, 2018-2020, single race results: deaths occurring through 2020. Centers for Disease Control and Prevention. Updated 2021. Accessed May 11, 2022. <https://wonder.cdc.gov/controller/datarequest/D157;jsessionid=C003973203296DC9773978C0CF93>
32. DEA laboratory testing reveals that 6 out of 10 fentanyl-laced fake prescription pills now contain a potentially lethal dose of fentanyl. News release. US Drug Enforcement Agency; November 22, 2022. Accessed March 7, 2023. <https://www.dea.gov/alert/dea-laboratory-testing-reveals-6-out-10-fentanyl-laced-fake-prescription-pills-now-contain>
33. Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. *Int J Drug Policy.* 2017;46:172-179.
34. Burns SM, Cunningham CW, Mercer SL. DARK classics in chemical neuroscience: fentanyl. *ACS Chem Neurosci.* 2018;9(10):2428-2437.
35. Opioid conversions calc (single agent) equianalgesic. Global RPH. Updated September 7, 2017. Accessed October 18, 2023. <https://globalrph.com/medcalcs/opioid-conversions-calc-original-single-agent>
36. Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention. Accessed October 18, 2023. <https://www.cdc.gov/opioids/providers/prescribing/pdf/calculating-total-daily-dose.pdf>
37. Zibbell J, Howard J, Duhart Clarke S, Ferrell A, Karon SL; RTI International. *Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report.* US Dept of Health and Human Services; September 2019. Accessed March 8, 2023. <https://aspe.hhs.gov/reports/non-fatal-opioid-overdose-associated-health-outcomes-final-summary-report>
38. Boyer EW. Management of opioid analgesic overdose. *N Engl J Med.* 2012;367(2):146-155.
39. Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. *World Psychiatry.* 2021;20(2):195-196.
40. Prescribing Information for FENTORA®.
41. Prescribing Information for LAZANDA®.
42. Prescribing Information for DURAGESIC®.
43. Marino M, Jamal Z, Zito PM. Pharmacodynamics. In: StatPearls [Internet]. StatPearls Publishing; 2023. Published January 29, 2023. Accessed May 17, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK507791>
44. Grogan S, Preuss CV. Pharmacokinetics. In: StatPearls [Internet]. StatPearls Publishing; 2023. Updated June 23, 2022. Accessed May 17, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK557744>
45. Fratantonio J, Hutton E, Skolnick P. A pharmacodynamic study comparing IN nalmefene to IN naloxone in healthy volunteers. Poster presented at: Annual Meeting of the American Association of Psychiatric Pharmacists; April 16-19, 2023; Atlanta, GA.
46. Data on file. Indivior Inc.; 2022.
47. Hallare J, Gerriets V. Half Life. In: StatPearls [Internet]. StatPearls Publishing; 2023. Updated June 23, 2022. Accessed May 5, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK554498>
48. REVIVE Antimicrobial Encyclopaedia: Cmax. Global Antibiotic Research & Development Partnership. Accessed March 14, 2023. <https://revive.gardp.org/resource/cmax>
49. REVIVE Antimicrobial Encyclopaedia: Tmax (time to peak drug concentration). Global Antibiotic Research & Development Partnership. Accessed March 14, 2023. <https://revive.gardp.org/resource/tmax-time-to-peak-drug-concentration>
50. Ahonen J, Olkkola KT, Hynynen M, et al. Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. *Br J Anaesth.* 2000;85(4):533-540.
51. Moss RB, Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. *Subst Abuse Treat Prev Policy.* 2019;14(1):6.
52. Drug plasma half-life and urine detection window. ARUP Laboratories. Published September 2022. Accessed October 18, 2023. <https://www.aruplab.com/files/resources/pain-management/DrugAnalytesPlasmaUrine.pdf>
53. Roca R. NDA 217470 approval letter: Opvee (nalmefene) nasal spray. US Food and Drug Administration; May 22, 2023. Accessed June 8, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2023/217470Orig1s000ltr.pdf



OPVEE® is a registered trademark of Indivior Inc.
INDIVIOR® is a registered trademark of Indivior UK Limited.
All other trademarks are the property of their respective owners.
© 2023 Indivior UK Limited. All Rights Reserved. P-OPV-US-00071



Signature Page for P-OPV-US-00071 v1.0

Medical Approval	Jordan Paavola Medical 04-Dec-2023 18:16:25 GMT+0000
------------------	--

Regulatory Approval	Michele Hardy Regulatory 04-Dec-2023 18:17:18 GMT+0000
---------------------	--

Legal Approval	Bryant Godfrey Legal 05-Dec-2023 18:07:11 GMT+0000
----------------	--

Owner Sign-Off	Jack Morin Job Owner 05-Dec-2023 19:14:29 GMT+0000
----------------	--

Coordinator Signoff	Rhavin Cooley Coordinator 05-Dec-2023 22:51:34 GMT+0000
---------------------	---

Signature Page for P-OPV-US-00071 v1.0